Biomea Fusion (BMEA) Q2 2026 earnings summary

Executive summary

• Focused on developing novel small molecule therapies for diabetes and obesity, with lead candidate icovamenib in Phase II trials for type 2 diabetes and recently completed Phase II for type 1 diabetes, showing durable C-peptide preservation.

• Advanced enrollment in two Phase II clinical trials for Type 2 diabetes, with data expected in Q1 and Q2 2027.

• BMF-650, a next-generation oral GLP-1 receptor agonist, is in Phase I for obesity, with topline and initial weight reduction data expected in Q3 2026.

• Research collaboration launched to evaluate icovamenib with semaglutide in obesity, with enrollment for the combination trial to begin in Q3 2026.

• Discontinued oncology studies to concentrate resources on metabolic disorders and exploring partnerships for oncology assets.

Financial highlights

• Net loss for the three months ended June 30, 2026 was $8.3 million, compared to $20.7 million for the same period in 2025.

• Net loss for the six months ended June 30, 2026 was $20.7 million, down from $50.0 million in the prior year period.

• Total operating expenses for the quarter were $12.8 million, a decrease from $21.3 million year-over-year, driven by lower R&D and G&A costs.

• Cash, cash equivalents, and restricted cash totaled $35.2 million as of June 30, 2026.

• Accumulated deficit reached $469.8 million as of June 30, 2026.

Outlook and guidance

• Current cash resources are expected to fund operations into Q2 2027, but management notes substantial doubt about the ability to continue as a going concern without additional financing.

• Anticipates continued significant operating losses as clinical development progresses and expects to raise additional capital through equity, debt, or partnerships.

• Data from ongoing Phase II diabetes trials expected in Q1 and Q2 2027.

• Initial 28-day weight reduction data from the Phase I obesity trial expected in Q3 2026.

• Enrollment for the obesity combination trial with semaglutide to begin in Q3 2026.